Aberdeen Health Sciences B
1735 Market Street 32nd Floor
Map
Phone: 866-667-9231
| Category: | Health | | Fund Family: | Aberdeen | | Net Assets: | 220.00K | | Year-to-Date Return: | 9.81% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 29-Dec-00 |
|
Douglas Burtnick
Lead Manager since
31-May-06 | | | Burtnick is an investment manager on the U.S. equity team. He joined Aberdeen in October 2007. Prior to that, he was a portfolio manager employed by NFA since May 2002. From 2000 to 2002, Burtnick served as a risk manager in the private client group of Brown Brothers Harriman & Company and was a portfolio manager. Burtnik holds the Chartered Financial Analyst designation |
| Min Initial Investment: | $2,000 | | Min Initial Investment, IRA: | $1,000 | | Min Initial Investment, AIP: | $1,000 | | Min Subsequent Investment: | $100 | | Min Subsequent Investment, IRA: | $100 | | Min Subsequent Investment, AIP: | $50 |
|
| |
| The investment seeks long-term capital appreciation. The fund invests at least 80% of net assets in equity securities issued by U.S. and foreign companies with business operations in or related to health sciences. It invests 25% or more of assets in at least one of the following industry groups: healthcare; pharmaceuticals; biotechnology; medical supplies; medical services and medical devices. The fund may invest in health sciences companies of any size, including established large-cap companies that are expected to grow with the market and small-cap and mid-cap companies that may offer strong prospects for future growth. It is nondiversified. |
| Last Dividend
| YFT_NOT_APPLICABLE_ABBREVIATION | | Last Cap Gain
(16-Jun-08):
| 0.24 | | Annual Holdings Turnover
| YFT_NOT_APPLICABLE_ABBREVIATION | | Average for Category:
| 109.30% |
|
| Expense | GLSBX | Category
Avg | | Total Expense Ratio: | 2.26%
| 1.67% | | Max 12b1 Fee: | 1.00%
| N/A | | Max Front End Sales Load: | %
| 5.35% | | Max Deferred Sales Load: | 5.00%
| 2.88% | | 3 Yr Expense Projection*: |
$ 1,068 | $716 | | 5 Yr Expense Projection*: |
$ 1,534 | $1,069 | | 10 Yr Expense Projection*: |
$ 2,643 | $2,090 |
|
|
1.93% Nasdaq 
Profile
